Clinical trial · Observational
Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer
NCT03367182CI-TRIAL-00036484REBECAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the efficacy and safety profile, response rate, progression free survival, overall survival of bevacizumab (Avastin) added to chemotherapy in patients with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma with disease progression within 6 months of platinum treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Pegylated liposomal doxorubicin | Drug | — | UNRESOLVED |
| Topotecan | Drug | Topotecan | ALIAS |
| Weekly paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (3)
- label
- Weekly paclitaxel + bevacizumab
- interventionNames
- Drug: Weekly paclitaxel
- Drug: Bevacizumab
- label
- Topotecan + bevacizumab
- interventionNames
- Drug: Topotecan
- Drug: Bevacizumab
- label
- Pegylated liposomal doxorubicin + bevacizumab
- interventionNames
- Drug: Pegylated liposomal doxorubicin
- Drug: Bevacizumab
Primary outcomes (2)
- measure
- Progression free survival (PFS)
- timeFrame
- 36 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who have histologically or cytologically confirmed recurrent epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer. 2. Patients who have platinum-resistant disease (defined as having relapsed within 6 months of her last platinum-containing regimen) 3. Patients who have underwent chemotherapy of either weekly paclitaxel + bevacizumab, topotecan + bevacizumab, pegylated liposomal doxorubicin + bevacizumab in 2nd line or 3rd line chemotherapy. Exclusion Criteria: 1. Patients with previous treatment with bevacizumab. 2. Patients who received bevacizumab combination therapy in 4th line or more chemotherapy.
References
Publications (1)
- DERIVEDLee JY, Park JY, Park SY, Lee JW, Kim JW, Kim YB, Jeong DH, Lee KB, Kim TH, Lee IH, Choi MC, Kim KH, Kim YM, Lee YJ, Kang S; KGOG Investigators; Pujade-Lauraine E. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041). Gynecol Oncol. 2019 Jan;152(1):61-67. doi: 10.1016/j.ygyno.2018.10.031. Epub 2018 Nov 6. PMID 30409490